XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Note 14 - Restructuring Costs
 9 Months Ended
Sep. 30, 2025
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]

14.

Restructuring Costs

 

On an ongoing basis, the Company reviews the global economy, the life sciences industry, and the markets in which it competes to identify operational efficiencies and align its cost base and infrastructure with customer needs and its strategic plans. In order to achieve these goals, the Company undertakes activities from time to time to optimize its business.

 

 

During the nine months ended September 30, 2025, the Company initiated additional restructurings for which it incurred $0.2 million of costs, primarily consisting of severance incurred in connection with headcount reductions in North America and Europe. The Company expects the restructuring to be completed during the year ending December 31, 2025.

 

During the nine months ended September 30, 2024, the Company completed a restructuring and incurred expenses of $0.6 million, primarily consisting of severance incurred in connection with headcount reductions in North America and Europe. Severance and other costs have been included as a component of other operating expenses (see Note 1). The changes in the accrued liability for restructuring and other charges for the nine months ended September 30, 2025 were as follows:

 

(in thousands)

  

Severance

 

Balance at December 31, 2024

   $ 82  

Restructuring costs

     171  

Cash payments

     (178 )

Effect of change in currency translation

     4  

Balance at September 30, 2025

   $ 79